Mingrone G
reported the first structures of the carnitine oxygenase CntA and identified MMV3 as a potential inhibitor of CntA
Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective DOI: 10.1590/2175-8239-JBN-2024-0101pt Graphical Abstract Click to view Abstract GLP1 receptor agonists (GLP1-RAs) are drugs that mimic the effects of the incretin hormone GLP1 and were initially introduced in medicine for the treatment of diabetes in 2005 and for obesity in 2014
Weiss T, Carr RD, Pal S, et al
J Neurochem 104:113123 Czeredys M, Mysiorek C, Kulikova N, Samluk L, Berezowski V, Cecchelli R, Nalecz KA (2008) A polarized localization of amino acid/carnitine transporter B(0,+) (ATB(0,+)) in the bloodbrain barrier
With the development of new anti-obesity medications, we hope this will encourage more active medical interventions for patients with severe obesity who have faced limitations in weight management despite lifestyle interventions." Lilly Korea Executive Director of Diabetes Business Unit and CMO Kim Kye-won also said, Despite extensive research and substantial scientific evidence, obesity patients in Korea still experience stigma and prejudice related to their weight. This can hinder patients' efforts to improve their health and negatively impact the quality of treatment they receive, Kim added
